Jamie Jl Liew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Jl Liew has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Billie Hunne
University of Melbourne The Florey Institute of Neuroscience and Mental Health SPARC University of Melbourne
2 shared publications - Georgia Ramsay
Department of General Practice and Primary Care and the Collaborative Centre for Genomic Cancer Medicine, The University of Melbourne
2 shared publications John Furness
University of Melbourne The Florey Institute of Neuroscience and Mental Health SPARC University of Melbourne
2 shared publications- Jon Emery
Nanyang Technological University 5 Singapore
2 shared publications - Madeleine R. Di Natale
Department of Anatomy & Physiology University of Melbourne Parkville Victoria Australia
2 shared publications - Martin James Stebbing
University of Melbourne The Florey Institute of Neuroscience and Mental Health SPARC University of Melbourne
2 shared publications
Latest Publications
- Open Access
- 7 August 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e329-e338
GP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk
Background: A polygenic risk score (PRS) enables personalisation of cancer risk and supporting risk stratification for melanoma, colorectal, breast, and prostate cancers. Including a PRS in a cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating an individual’s age, sex, family history, and genomic test results. GPs are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models. Aim: To elucidate GPs’ perspectives on the use of PRSs to tailor cancer screening in the Australian primary care context. Design & setting: A qualitative study undertaken in Victoria, Australia with GPs involved in a series of studies and clinical trials evaluating PRS. Method: Thirty GPs were interviewed; they were either PRS naive or had experience of using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia. Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research. Results: Common themes identified were: general practice is the appropriate setting for PRS-based approaches, personalised approaches to cancer risk can prompt discussions about positive lifestyle changes, and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included: time constraints on the delivery of preventative health care, education requirements to upskill GPs in genomics, possible psychosocial harms to patients identified as being at increased risk, life-insurance implications, and added pressure on an already struggling health system. Conclusion: These findings provide insight into the requirements for the implementation of PRSs in primary care, from the perspective of GPs.
- 7 August 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e329-e338
Open AccessGP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk
Background: A polygenic risk score (PRS) enables personalisation of cancer risk and supporting risk stratification for melanoma, colorectal, breast, and prostate cancers. Including a PRS in a cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating an individual’s age, sex, family history, and genomic test results. GPs are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models. Aim: To elucidate GPs’ perspectives on the use of PRSs to tailor cancer screening in the Australian primary care context. Design & setting: A qualitative study undertaken in Victoria, Australia with GPs involved in a series of studies and clinical trials evaluating PRS. Method: Thirty GPs were interviewed; they were either PRS naive or had experience of using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia. Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research. Results: Common themes identified were: general practice is the appropriate setting for PRS-based approaches, personalised approaches to cancer risk can prompt discussions about positive lifestyle changes, and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included: time constraints on the delivery of preventative health care, education requirements to upskill GPs in genomics, possible psychosocial harms to patients identified as being at increased risk, life-insurance implications, and added pressure on an already struggling health system. Conclusion: These findings provide insight into the requirements for the implementation of PRSs in primary care, from the perspective of GPs.
- Open Access
- 19 May 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-18
The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
- 19 May 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-18
Open AccessThe PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
- Open Access
- 24 January 2022
- Published by Springer Nature
Immunohistochemistry in wholemounts and cryostat sections in rat stomach v1
This protocol describes the methods used to evaluate neuronal target and population density in wholemount preparations and cryostat sections. In brief, stomachs from Sprague-Dawley rats were collected, fixed, cleared, and processed before being immunohistochemically stained with primary antibody and fluorescent secondary antibodies. Neuronal density and neuronal target analysis were completed using Zen Blue analysis software.
- 24 January 2022
- Published by Springer Nature
Open AccessImmunohistochemistry in wholemounts and cryostat sections in rat stomach v1
This protocol describes the methods used to evaluate neuronal target and population density in wholemount preparations and cryostat sections. In brief, stomachs from Sprague-Dawley rats were collected, fixed, cleared, and processed before being immunohistochemically stained with primary antibody and fluorescent secondary antibodies. Neuronal density and neuronal target analysis were completed using Zen Blue analysis software.
- Open Access
- 10 January 2022
- Published by Springer Nature
NADPH diaphorase histochemistry in rat gastric nitric oxide synthase neurons v1
NOS (nitric oxide synthase) is a NADPH oxidase, requiring NADPH as a proton donor for the conversion of arginine to citrulline and the production of nitric oxide (NO). Thus nitrergic neurons can be localised by nNOS immunoreactivity or histochemically, using the NADPH diaphorase reaction (Young et al. 1992) to enable investigation of their morphology.
- 10 January 2022
- Published by Springer Nature
Open AccessNADPH diaphorase histochemistry in rat gastric nitric oxide synthase neurons v1
NOS (nitric oxide synthase) is a NADPH oxidase, requiring NADPH as a proton donor for the conversion of arginine to citrulline and the production of nitric oxide (NO). Thus nitrergic neurons can be localised by nNOS immunoreactivity or histochemically, using the NADPH diaphorase reaction (Young et al. 1992) to enable investigation of their morphology.
- 30 August 2021
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (5) , 1665-1674
A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function
- 30 August 2021
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (5) , 1665-1674
A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function